IOVANCE BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $861.00K, a 28.70% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $839.00K, a 39.64% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $3.00K.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $669.00K, a 57.17% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.51M, a 48.85% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $2.95M, a 22.49% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $2.41M, a 45.62% increase from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.66M, a 4.35% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $861.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.51M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $669.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.95M 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $1.56M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.41M 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $1.27M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.66M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2022-06-30 | $582.00K 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $616.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.59M 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2021-06-30 | $970.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |